<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31925813</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2990</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neuropathology and applied neurobiology</Title><ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Spatial transcriptomics identifies spatially dysregulated expression of GRM3 and USP47 in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>441</StartPage><EndPage>457</EndPage><MedlinePgn>441-457</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/nan.12597</ELocationID><Abstract><AbstractText Label="AIMS">The mechanisms underlying the selective degeneration of motor neurones in amyotrophic lateral sclerosis (ALS) are poorly understood. The aim of this study was to implement spatially resolved RNA sequencing in human post mortem cortical tissue from an ALS patient harbouring the C9orf72 hexanucleotide repeat expansion to identify dysregulated transcripts that may account for differential vulnerabilities of distinct (i) cell types and (ii) brain regions in the pathogenesis of ALS.</AbstractText><AbstractText Label="METHODS">Using spatial transcriptomics (ST) we analysed the transcriptome of post mortem brain tissue, with spatial resolution down to 100&#xa0;&#x3bc;m. Validation of these findings was then performed using BaseScope, an adapted, in situ hybridization technique with single-transcript single-cell-resolution, providing extensive regional and cell-type specific confirmation of these dysregulated transcripts. The validation cohort was then extended to include multiple post mortem brain regions and spinal cord tissue from an extended cohort of C9orf72, sporadic ALS (sALS) and SOD1 ALS cases.</AbstractText><AbstractText Label="RESULTS">We identified sixteen dysregulated transcripts of proteins that have roles within six disease-related pathways. Furthermore, these complementary molecular pathology techniques converged to identify two spatially dysregulated transcripts, GRM3 and USP47, that are commonly dysregulated across sALS, SOD1 and C9orf72 cases alike.</AbstractText><AbstractText Label="CONCLUSIONS">This study presents the first description of ST in human post mortem cortical tissue from an ALS patient harbouring the C9orf72 hexanucleotide repeat expansion. These data taken together highlight the importance of preserving spatial resolution, facilitating the identification of genes whose dysregulation may in part underlie regional susceptibilities to ALS, crucially highlighting potential therapeutic and diagnostic targets.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley &amp; Sons Ltd on behalf of British Neuropathological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>J M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-3337-4079</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Edinburgh Pathology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Edinburgh Pathology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livesey</LastName><ForeName>M R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croy</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Edinburgh Pathology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marion de Proce</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aitman</LastName><ForeName>T</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7875-4502</Identifier><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>C</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4507-5132</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Edinburgh Pathology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100616</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_15080</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SGP/1</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N005902/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L016400/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropathol Appl Neurobiol</MedlineTA><NlmUniqueID>7609829</NlmUniqueID><ISSNLinking>0305-1846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C557800">USP47 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C104723">glutamate receptor ionotropic, AMPA 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="D043222">Ubiquitin Thiolesterase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="D064570">Ubiquitin-Specific Proteases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016591" MajorTopicYN="N">Histocytological Preparation Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043222" MajorTopicYN="N">Ubiquitin Thiolesterase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064570" MajorTopicYN="N">Ubiquitin-Specific Proteases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">
post mortem
</Keyword><Keyword MajorTopicYN="N">BaseScope</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">molecular pathology</Keyword><Keyword MajorTopicYN="N">spatial transcriptomics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31925813</ArticleId><ArticleId IdType="doi">10.1111/nan.12597</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Corcia P, Couratier P, Blasco H, Andres CR, Beltran S, Meininger V, et al. Genetics of amyotrophic lateral sclerosis. Rev Neurol 2017; 173: 254-262</Citation></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat JM, Masson GL. Genetics of amyotrophic lateral sclerosis: a review. J Neurol Sci 2019; 15: 217-226</Citation></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 20: 245-56</Citation></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011 20: 257-68</Citation></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013; 20: 639-46</Citation></Reference><Reference><Citation>Reddy K, Zamiri B, Stanley SY, Macgregor RB Jr, Pearson CE. The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures. J Biol Chem 2013; 5: 9860-6</Citation></Reference><Reference><Citation>Ciura S, Lattante S, Le Ber I, Latouche M, Tostivint H, Brice A, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 180-7</Citation></Reference><Reference><Citation>Devenney E, Foxe D, Dobson-Stone C, Kwok JB, Kiernan MC, Hodges JR. Clinical heterogeneity of the C9orf72 genetic mutation in frontotemporal dementia. Neurocase 2015; 21: 535-41</Citation></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature 2016; 10: 197-206</Citation></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 6: 130-3</Citation></Reference><Reference><Citation>Ince PG, Highley JR, Kirby J, Wharton SB, Takahashi H, Strong MJ, et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 2011; 122: 657-71</Citation></Reference><Reference><Citation>Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, et al. Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14(Suppl. 1): 5-18.</Citation></Reference><Reference><Citation>St&#xe5;hl PL, Salm&#xe9;n F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, et al. Visualisation and analysis of gene expression in tissue sections by spatial transcriptomics. Science 2016; 1: 78-82</Citation></Reference><Reference><Citation>Maniatis S, &#xc4;ij&#xf6; T, Vickovic S, Braine C, Kang K, Mollbrink A, et al. Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. Science 2019; 5: 89-93</Citation></Reference><Reference><Citation>Ferreira PG, Mu&#xf1;oz-Aguirre M, Reverter F, S&#xe1; Godinho CP, Sousa A, Amadoz A, et al. The effects of death and post-mortem cold ischemia on human tissue transcriptomes. Nat Commun 2018; 13: 490</Citation></Reference><Reference><Citation>Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, et al. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol 2011; 122: 691-702</Citation></Reference><Reference><Citation>Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2012; 14: 22-9</Citation></Reference><Reference><Citation>Navarro JF, Sj&#xf6;strand J, Salm&#xe9;n F, Lundeberg J, St&#xe5;hl PL. ST Pipeline: an automated pipeline for spatial mapping of unique transcripts. Bioinformatics 2017; 15: 2591-2593</Citation></Reference><Reference><Citation>Ebbert MTW, Ross CA, Pregent LJ, Lank RJ, Zhang C, Katzman RB, et al. Conserved DNA methylation combined with differential frontal cortex and cerebellar expression distinguishes C9orf72-associated and sporadic ALS, and implicates SERPINA1 in disease. Acta Neuropathol 2017; 134: 715-728</Citation></Reference><Reference><Citation>Harrison PJ, Lyon L, Sartorius LJ, Burnet PW, Lane TA. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 2008; 22: 308-22</Citation></Reference><Reference><Citation>Cozzi A, Attucci S, Peruginelli F, Marinozzi M, Luneia R, Pellicciari R, et al. Type 2 metabotropic glutamate (mGlu) receptors tonically inhibit transmitter release in rat caudate nucleus: in vivo studies with (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a new potent and selective antagonist. Eur J Neurosci 1997; 9: 1350-5</Citation></Reference><Reference><Citation>Battaglia G, Monn JA, Schoepp DD. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group IImetabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 1997; 229: 161-4</Citation></Reference><Reference><Citation>Lovinger DM, McCool BA. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J Neurophysiol 1995; 73: 1076-83</Citation></Reference><Reference><Citation>Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 2000; 75: 889-907</Citation></Reference><Reference><Citation>Corti C, Battaglia G, Molinaro G, Riozzi B, Pittaluga A, Corsi M, et al. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamatereceptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci 2007; 27: 8297-308</Citation></Reference><Reference><Citation>Battaglia G, Riozzi B, Bucci D, Di Menna L, Molinaro G, Pallottino S, et al. Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateralsclerosis. Neurobiol Dis 2015; 74: 126-36. https://doi.org/10.1016/j.nbd.2014.11.012. Epub 2014 Nov 28</Citation></Reference><Reference><Citation>Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry 2009; 166: 812-20. https://doi.org/10.1176/appi.ajp.2009.08091445. Epub 2009 Jun 1</Citation></Reference><Reference><Citation>Garc&#xed;a-Bea A, Bermudez I, Harrison PJ, Lane TA. A group II metabotropic glutamate receptor 3 (mGlu3, GRM3) isoform implicated in schizophrenia interacts with canonical mGlu3 and reduces ligand binding. J Psychopharmacol 2017; 31: 1519-1526</Citation></Reference><Reference><Citation>O'Brien M, Burke T, Heverin M, Vajda A, McLaughlin R, Gibbons J, et al. Clustering of neuropsychiatric disease in first-degree and second-degree relatives of patients with amyotrophic lateral sclerosis. JAMA Neurol 2017; 74: 1425-1430</Citation></Reference><Reference><Citation>Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 2008; 196: 431-40</Citation></Reference><Reference><Citation>Fujioka R, Nii T, Iwaki A, Shibata A, Ito I, Kitaichi K, et al. Comprehensive behavioral study of mGluR3 knockout mice: implication in schizophrenia related endophenotypes. Molecular Brain 2014; 7: 31</Citation></Reference><Reference><Citation>Mackenzie IR, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol 2014; 127: 347-57</Citation></Reference><Reference><Citation>Ao N, Chen Q, Liu G. The small molecules targeting ubiquitin-proteasome system for cancer therapy. Comb Chem High Throughput Screen 2017; 20: 403-413</Citation></Reference><Reference><Citation>Peschiaroli A, Skaar JR, Pagano M, Melino G. The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survival. Oncogene 2010; 29: 1384-93</Citation></Reference><Reference><Citation>Yang SW, Oh KH, Park E, Chang HM, Park JM, Seong MW, et al. USP47 and C terminus of Hsp70-interacting protein (CHIP) antagonistically regulate katanin-p60-mediated axonal growth. J Neurosci 2013; 33: 12728-12738.</Citation></Reference><Reference><Citation>Prudencio M, Belzil VV, Batra R, Ross CA, Gendron TF, Pregent LJ, et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci 2015; 18: 1175-82</Citation></Reference><Reference><Citation>Eng CL, Lawson M, Zhu Q, Dries R, Koulena N, Takei Y, et al. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature 2019; 568: 235-239</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>